Comprehensive Approach to the Polycystic Kidney Disease Patient: Clinical and Therapeutic Strategies in the Management of a Multifaceted Pathology
Main Article Content
Abstract
Polycystic kidney disease (PKD) is a heterogeneous, inherited clinical entity characterized by the formation of renal cysts, which can manifest with a wide range of symptoms and complications. This article comprehensively reviews advances in the diagnosis and treatment of PKD, highlighting the importance of a multidisciplinary approach ranging from primary care to specialized care in nephrology and urology. Management strategies for major symptoms such as low back pain, hypertension, and urologic complications are discussed, as well as the most recent therapeutic options, including vasopressin inhibitors and ongoing clinical trials.
Furthermore, it highlights the relevance of patient education and early detection in the management of this pathology, in order to improve the quality of life and survival of patients with PKD. This article provides a comprehensive overview of the management of PKD, with a focus on the latest research and therapies, to guide health care professionals in making informed clinical decisions and providing patients with high-quality care in the context of this complex renal disease.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Soroka S, Alam A, Bevilacqua, Girard LPh, Komenda P, Loertscher R et al. Assessing Risk of Disease Progression and Pharmacological Management of ADPKD: A Canadian Expert Consensus. Can J of Kidney Health and Disease 2017; 4:1-12.
II. International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell 1995; 81:289-98.
III. Mochizuki T, Wu g, Hayashi T et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272:1339-42.
IV. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76:149-168.
V. Cai Y, Fedeles SV, Dong K, et al. Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest 2014; 124: 512944.
VI. Cornec-Le Gall E, Audrezet MP, Le Meur Y, Chen JM, Ferec C. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. Hum Mut 2014; 35: 1393406.
VII. Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 2018; 29: 1323.
VIII. Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, encoding the glucosidase iialpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 2016; 98: 1193-207.
IX. Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 2018; 102: 832-44.
X. Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477-85.
XI. Seeger-Nukpezah T, Geynisman DM, Nikonova AS, et al. The hallmarks of cancer: relevanceto the pathogenesis of polycystic kidney disease. Nat Rev Nephrol 2015; 11:515-34.
XII. Qian Q, Li A, King B, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003; 37:164-71.
XIII. Boucher C and Sandford R. Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 an polycystin-2). Eur J Hum Genet 2004; 12:347-54.
XIV. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE: Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:1274-85.